Roivant reports Q4 net loss $0.39, VTAMA approved, $2.1B cash, pipeline reprioritized

Roivant Sciences Ltd.

Net loss $291M in Q4 ($0.39/share); full-year net loss $924M ($1.26/share); revenue $9.2M Q4 vs $15.1M prior year.
VTAMA (tapinarof) approved by FDA for plaque psoriasis in May; launch underway with 100+ person commercial team.
Cash and equivalents $2.1B; company discontinued several programs including ARU-1801, DMVT-502/503/504.
Melissa Epperly appointed to Board of Directors effective June 29, replacing Pat Machado.
Pipeline milestones: Priovant initiated Phase 3 for brepocitinib in dermatomyositis; Immunovant Phase 3 in MG started.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Patrick Machado

Director

ROIV · Roivant Sciences Ltd.

Effective: 2022-06-29
Successor: Melissa Epperly
Filed: June 28, 2022, 7:59 PM ET

the previously announced resignation of Patrick Machado from the Board

Appointed

Melissa Epperly

Director

ROIV · Roivant Sciences Ltd.

Effective: 2022-06-29
Filed: June 28, 2022, 7:59 PM ET

On June 22, 2022, the Board of Directors (the “Board”) of the Company appointed Melissa Epperly to serve as a Class I director of the Board and as a member of the Audit Committee of the Board, effective June 29, 2022, filling the vacancy created by, and concurrent with, the previously announced resignation of Patrick Machado from the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Patrick Machado resigned as Director at Roivant Sciences Ltd..

Action: resigned
Role: Director

Exact text from the filing

the previously announced resignation of Patrick Machado from the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Melissa Epperly was appointed as Director at Roivant Sciences Ltd..

Action: appointed
Role: Director

Exact text from the filing

On June 22, 2022, the Board of Directors (the “Board”) of the Company appointed Melissa Epperly to serve as a Class I director of the Board and as a member of the Audit Committee of the Board, effective June 29, 2022, filling the vacancy created by, and concurrent with, the previously announced resignation of Patrick Machado from the Board.

View on SEC.gov

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-22-183258

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.